Baxter South Central Europe & Israel’s Post

Prof. Fredric O. Finkelstein, M.D., is joining Byonyks as a scientific advisor. Before joining the company, he wrote the following article. I'm excited to share that it validates the important work we are doing at Byonyks to revolutionize peritoneal dialysis (PD). The article published in Kidney International Reports highlights the critical need for innovations in PD to reduce inflammation, preserve the peritoneal membrane, and improve patient comfort and outcomes. As the article states, "Innovations in PD are needed to improve patient outcomes and quality of life." This is precisely the mission we are pursuing at Byonyks - to develop next-generation PD devices that are biocompatible, toxin-free, and help preserve peritoneal membrane integrity. Our solutions aim to deliver higher-quality treatments more efficiently, allowing patients to maintain an active lifestyle. We are excited to bring real innovation to the PD space and partner with the nephrology community to elevate patient care. Stay tuned for more updates as we work to commercialize our solutions in the US market. Link: https://lnkd.in/gWSAbUj8

#OpenAccess Miano et al: What factors influence implementation of “race-free” creatinine & cystatin C-based kidney function equations? Society of Critical Care Medicine #DEI in Renal Clinical Practice Task Force @ASNKidney National Kidney Foundation Link: https://ow.ly/iAcX50RMotL #CritCareMed #renalICU Fig: Nonrenal determinants of creatinine & role of race

Kidneys are essential organs for the body, they create a special filter to remove waste products from the system and regulate the levels of water and various substances in the blood. But how do kidneys work exactly? And what happens to a patient when they stop functioning? Prolonged (end stage) kidney failure usually requires the patient to go on dialysis and may eventually result in the need of an organ transplant. Learn more about kidney function in the slideshow and discover the "Take 2" campaign on https://lnkd.in/dm5qbYru #take2 #kidneyfunction #dialysis #transplant #PoweredByESOT with the unconditional unrestricted grant of Chiesi Group

The artificial kidney market size is projected to grow from USD 0.16 Billion in 2023 to USD 7.00 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 60.33% during the forecast period (2023 - 2032), according to Market Research Future Get More Details at: https://lnkd.in/d3e2Vdwh The #artificialkidney represents a groundbreaking advancement in medical technology, aiming to revolutionize renal care. Unlike traditional dialysis machines, which offer only partial kidney function, artificial kidneys mimic the organ's complex filtration processes. This compact and portable device is designed to provide continuous blood purification, eliminating toxins and excess fluids more efficiently. Its potential to enhance patients' quality of life by reducing the burden of regular dialysis sessions is significant. Additionally, the artificial kidney offers hope for those awaiting #transplant, bridging the gap between organ scarcity and the growing demand for #lifesaving interventions. As research and development progress, this innovative solution holds promise for transforming renal #healthcare globally. The prominent key players of the artificial kidney market are @Kawasumi Laboratories Inc., Blood Purification Technologies Inc., AWAK Technologies Pte. Ltd, Trimmed AB, Asahi Kasei Medical Vo. Ltd, US Kidney Research Corporation, Merit Medical Systems, Inc., Nipro Medical Corporation, Fresenius SE & Co. KGaA #KidneyHealthTech #OrganTransplant #KidneyTreatment #MedicalTechnology #ArtificialOrgans #PatientCare #MarketResearchFuture #marketresearch #consultingservices #consultingfirms #consultingbusiness #mrfr

Crearene, Alzchem and University Medical Center of Groningen today announce headline results of a recently concluded clinical study administrating creatine during hemodialysis. Full results with data analysis are expected until end of Q2/2024 . A feasibility-, safety- and dose finding study conducted by a University Medical Center Groningen team with principal investigator Prof. Dr. Stephan J.L. Bakker, supported by Crearene AG, using specially purified creatine provided by the Alzchem group, has recently successfully concluded patient treatment in a double-blind study setting, with four different patient groups and a 3:1 randomization. The primary endpoint of the study, the demonstration of the technical feasibility of simultaneous creatine administration during hemodialysis treatment, has been met. The study also confirmed that simultaneous administration of creatine during the dialysis process to patients with end stage chronic kidney disease is well tolerated. Furthermore, the study informed on the dose-response curve. Efficacy endpoints, which have been assessed in addition, have been very encouraging with final analysis still to be completed. Crearene AG and Alzchem Group AG have recently extended their co-operation on developing and commercializing Creavitalis® / creatine-based treatments solutions for dialysis patients. Based on the combination of the patented know-how of Crearene, result of many years of research in the field of creatine, and the manufacturing excellence of Alzchem the partners hope to be able to enable improved treatment options for the more than three million dialysis patients globally. www.crearene.com/media/ www.alzchem.com www.umcg.nl #creatine #creatineindialysis #dialysisinnovation #alzchem #crearene #umcg #creavitalis 

What are the seven things you should know about Tramadol? In the latest PharmaAdvice article from Dr Geraldine Moses, find out why you need to consider these key pointers before prescribing it. Find out more via

Dyne Bio Inc. proudly presents the remarkable findings from a 16-week clinical trial of Dyne-NAO®, published in BMC Complementary Medicine and Therapies. This double-blind, placebo-controlled study reveals Dyne-NAO®'s significant impact on weight management in overweight and obese individuals. Key Outcomes: ✨ Substantial reduction in Visceral Fat Area (VFA) ✨ Decrease in Visceral-to-Subcutaneous Ratio (VSR) ✨ Weight and BMI significantly reduced compared to the placebo group ✨ A tendency for increased HDL-C levels in the NAOs group ✨ Absolute Safety Substantiation of NAOs for Human This pioneering study demonstrates Dyne-NAO®'s potential as a safe and effective anti-obesity supplement, offering promising benefits for those seeking healthier weight management solutions. Dive into the full study here for an in-depth understanding: https://lnkd.in/gkYziUG5 #DyneNAO #ClinicalResearch #WeightManagement #HealthInnovation

🌐 Thrilled to be at the EuroPD Policy Forum with Sotiroula, diving into important discussions on Home Therapies in Europe! The topics envolved: Dialysis Provider Motivation, Empowering Patients, and Professional Education. Tackling challenges, including Staffing shortages. Working together for positive changes in renal care! #EuroPD #EDTNAERCA #HealthcareDialogue 🚀